These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 3154307)

  • 41. Differences in first dose response to angiotensin converting enzyme inhibition in congestive heart failure: a placebo controlled study.
    MacFadyen RJ; Lees KR; Reid JL
    Br Heart J; 1991 Sep; 66(3):206-11. PubMed ID: 1657084
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Therapy of chronic heart failure with angiotensin-converting enzyme inhibitors].
    Schofer J
    Dtsch Med Wochenschr; 1988 Oct; 113(43):1684-9. PubMed ID: 2846252
    [No Abstract]   [Full Text] [Related]  

  • 43. Renin inhibition: a novel therapy for cardiovascular disease.
    Lin C; Frishman WH
    Am Heart J; 1996 May; 131(5):1024-34. PubMed ID: 8615291
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Progression of chronic renal insufficiency and its prevention using angiotensin converting enzyme inhibitors and angiotensin antagonists].
    Tesar V
    Vnitr Lek; 2003 May; 49(5):365-9. PubMed ID: 12908169
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of the effect of renin inhibition and angiotensin-converting enzyme inhibition in ovine heart failure.
    Fitzpatrick MA; Rademaker MT; Charles CJ; Yandle TG; Espiner EA; Ikram H; Nussberger J
    J Cardiovasc Pharmacol; 1992 Feb; 19(2):169-75. PubMed ID: 1376784
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives.
    Azizi M; Chatellier G; Guyene TT; Murieta-Geoffroy D; Ménard J
    Circulation; 1995 Aug; 92(4):825-34. PubMed ID: 7641363
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Inhibition of renin-angiotensin-aldosterone system: what evidence?].
    Mota T
    Rev Port Cardiol; 2001 Mar; 20 Suppl 3():13-5. PubMed ID: 11409069
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of chronic angiotensin II type I receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic variables in patients with heart failure.
    Davie AP; Rumley A; Lowe GD; McMurray JJ
    Thromb Haemost; 2001 Dec; 86(6):1585-6. PubMed ID: 11776334
    [No Abstract]   [Full Text] [Related]  

  • 49. Differing early blood pressure and renin-angiotensin system responses to the first dose of angiotensin-converting enzyme inhibitors in congestive heart failure.
    Squire IB; MacFayden RJ; Reid JL; Devlin A; Lees KR
    J Cardiovasc Pharmacol; 1996 May; 27(5):657-66. PubMed ID: 8859935
    [TBL] [Abstract][Full Text] [Related]  

  • 50. How should we modify recommended renin-angiotensin-aldosterone system inhibition when facing the cardiorenal syndrome?
    Sexton DJ
    Circ Heart Fail; 2014 May; 7(3):536. PubMed ID: 24847129
    [No Abstract]   [Full Text] [Related]  

  • 51. Pharmacology of angiotensin-converting enzyme inhibitors as a guide to their use in congestive heart failure.
    Cody RJ
    Am J Cardiol; 1990 Oct; 66(11):7D-11D; discussion 11D-13D. PubMed ID: 2220605
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Medical agents acting on the renin-angiotensin-aldosterone axis for the treatment of heart failure.
    Kawano H; Node K
    Hypertens Res; 2010 Mar; 33(3):192-3. PubMed ID: 20203682
    [No Abstract]   [Full Text] [Related]  

  • 53. Combination therapy with ACE inhibitors and angiotensin-receptor blockers in heart failure.
    Scow DT; Smith EG; Shaughnessy AF
    Am Fam Physician; 2003 Nov; 68(9):1795-8. PubMed ID: 14620599
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Aldosterone and artery compliance in heart failure.
    Struthers A
    Eur Heart J; 1998 Sep; 19(9):1273. PubMed ID: 9792248
    [No Abstract]   [Full Text] [Related]  

  • 56. Effect of the insertion/deletion polymorphism of the angiotensin-converting enzyme gene on response to angiotensin-converting enzyme inhibitors in patients with heart failure.
    O'Toole L; Stewart M; Padfield P; Channer K
    J Cardiovasc Pharmacol; 1998 Dec; 32(6):988-94. PubMed ID: 9869506
    [TBL] [Abstract][Full Text] [Related]  

  • 57. ADEPT: Addition of the AT1 receptor antagonist eprosartan to ACE inhibitor therapy in chronic heart failure trial: hemodynamic and neurohormonal effects.
    Murdoch DR; McDonagh TA; Farmer R; Morton JJ; McMurray JJ; Dargie HJ
    Am Heart J; 2001 May; 141(5):800-7. PubMed ID: 11320369
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparative studies on differential inhibition of the renin - angiotensin system in the anesthetized guinea pig.
    Duan J; Jaramillo J; Jung GL; McLeod AL; Fernandes BH; Mathis D
    Can J Physiol Pharmacol; 1995 Oct; 73(10):1512-8. PubMed ID: 8748944
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Inhibitors of the renin-angiotensin system in established cardiac failure.
    Chatterjee K
    Heart; 1996 Nov; 76(3 Suppl 3):83-91. PubMed ID: 8977368
    [No Abstract]   [Full Text] [Related]  

  • 60. Effects of angiotensin receptor antagonists in heart failure: clinical and experimental aspects.
    Regitz-Zagrosek V; Neuss M; Fleck E
    Eur Heart J; 1995 Dec; 16 Suppl N():86-91. PubMed ID: 8682068
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.